Login / Signup

Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses.

Toshihiko MatsumotoYosuke YamamotoYusuke KurionaUkyo OkazakiShogo KimuraKou MiuraTakao TsudukiTakanori WatanabeYusuke MastumotoMasahiro Takatani
Published in: BMC cancer (2020)
Nivolumab is feasible but insufficient as third- or later-line treatment for AGC patients with poor PS.
Keyphrases
  • neoadjuvant chemotherapy
  • radiation therapy
  • combination therapy
  • replacement therapy